Michael T Lewis
Overview
Explore the profile of Michael T Lewis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
6296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arriojas A, Baek L, Berner M, Zhurkevich A, Hinton A, Meyer M, et al.
bioRxiv
. 2025 Mar;
PMID: 40027627
Advancements in transmission electron microscopy (TEM) have enabled in-depth studies of biological specimens, offering new avenues to large-scale imaging experiments with subcellular resolution. Mitochondrial structure is of growing interest in...
2.
Somes L, Lei J, Yi X, Chamorro D, Shafer P, Gad A, et al.
Mol Ther
. 2025 Feb;
PMID: 39980195
Triple-negative breast cancer (TNBC) remains one of the most challenging subtypes of breast cancer to treat due to a lack of effective targeted therapies. Chimeric antigen receptor (CAR)-T cells hold...
3.
Park J, Jung K, Jia D, Yang S, Attri K, Ahn S, et al.
Cell Rep Med
. 2025 Feb;
6(2):101941.
PMID: 39933530
The biguanide metformin attenuates mitochondrial oxidation and is proposed as an anti-cancer therapy. However, recent clinical studies suggest increased proliferation and fatty acid β-oxidation (FAO) in a subgroup of patients...
4.
Sederman C, Yang C, Cortes-Sanchez E, Di Sera T, Huang X, Scherer S, et al.
bioRxiv
. 2025 Jan;
PMID: 39763776
Precision oncology matches tumors to targeted therapies based on the presence of actionable molecular alterations. However, most tumors lack actionable alterations, restricting treatment options to cytotoxic chemotherapies for which few...
5.
Lei J, Dobrolecki L, Huang C, Srinivasan R, Vasaikar S, Lewis A, et al.
bioRxiv
. 2024 Dec;
PMID: 39713418
Combination chemotherapy remains essential for clinical management of triple-negative breast cancer (TNBC). Consequently, responses to multiple single agents cannot be delineated at the single patient level, even though some patients...
6.
Awasthi S, Dobrolecki L, Sallas C, Zhang X, Li Y, Khazaei S, et al.
Cell Rep Med
. 2024 Dec;
5(12):101834.
PMID: 39626673
Therapeutic strategies targeting the DNA damage response, such as poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), have revolutionized cancer treatment in tumors deficient in homologous recombination (HR). However, overcoming innate and...
7.
Xu L, Peng F, Luo Q, Ding Y, Yuan F, Zheng L, et al.
Cell
. 2024 Oct;
187(25):7248-7266.e34.
PMID: 39419025
Chemotherapy is often combined with immune checkpoint inhibitor (ICIs) to enhance immunotherapy responses. Despite the approval of chemo-immunotherapy in multiple human cancers, many immunologically cold tumors remain unresponsive. The mechanisms...
8.
Berner M, Beasley H, Vue Z, Lane A, Vang L, Baek M, et al.
bioRxiv
. 2024 Sep;
PMID: 39314272
Mitochondria are hubs of metabolism and signaling and play an important role in tumorigenesis, therapeutic resistance, and metastasis in many cancer types. Various laboratory models of cancer demonstrate the extraordinary...
9.
White B, Woo X, Koc S, Sheridan T, Neuhauser S, Wang S, et al.
Cancer Res
. 2024 Jul;
84(13):2060-2072.
PMID: 39082680
Patient-derived xenografts (PDX) model human intra- and intertumoral heterogeneity in the context of the intact tissue of immunocompromised mice. Histologic imaging via hematoxylin and eosin (H&E) staining is routinely performed...
10.
Meric-Bernstam F, Lloyd M, Koc S, Evrard Y, McShane L, Lewis M, et al.
Mol Cancer Ther
. 2024 Apr;
23(7):924-938.
PMID: 38641411
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating...